Amarin Corporation (AMRN) Corporate presentation summary

Strategic transformation and operational progress

• Implemented a refined global business model in mid-2025, resulting in a leaner, more focused, and financially stronger organization.

• Substantially completed global restructuring, leading to a materially lower fixed cost structure and a debt-free balance sheet.

• Achieved cash flow positivity for the second consecutive quarter in Q1 2026, with expectations for full-year positive cash flow.

Product leadership and scientific validation

• First and only FDA-approved oral therapy to reduce cardiovascular risk when added to statin therapy.

• VASCEPA (icosapent ethyl) demonstrated a 25% relative risk reduction for cardiovascular events on top of statin therapy.

• Over 30 million prescriptions written and more than $3.5 billion in cumulative sales since 2013.

• Recognized in over 70 medical society guidelines globally and included in the 2026 ACC/AHA Dyslipidemia Guideline.

Global commercial strategy and partnerships

• Fully partnered international commercial strategy covers nearly 100 countries, with a focus on Europe and strong IP protection through 2039.

• Seven ex-U.S. partnerships actively building market opportunities, with launches and regulatory approvals progressing across multiple continents.

• Recordati partnership in Europe includes a 15-year license, upfront and milestone payments, and supply-based revenues.